Dr. Katz is an endourologist focused on the treatment of benign prostatic enlargement and the surgical and metabolic treatment of kidney stones. After earning his M.D. and completing his urology residency at the University of Miami, he completed a fellowship in Endourology and Minimally Invasive Surgery in a joint program at the University of California, San Diego and Kaiser Permanente. Dr. Katz is the co-director of the Guided Lithotripsy with Directed Endoscopic Robot (GLiDER) lab and is a co-founder of StonePreventURS.com.

Puneet Masson, MD is a Board-Certified Urologist who earned his medical degree from the Columbia University College of Physicians and Surgeons. He completed a 6-year Urology residency at New York Presbyterian Hospital – Weill Cornell Medical Center, followed by an Andrology and Male Fertility fellowship at Northwestern University’s Feinberg School of Medicine.

Dr. Masson serves as an Associate Professor and the Director of Reproductive Urology at the University of Miami. Previously, he was the Regional Medical Director and VP of Clinical Engagement at Posterity Health, which is a network of reproductive urologists throughout the US. Prior to Posterity Health, Dr. Masson was an Associate Professor of Clinical Urology and Director of Male Reproductive Medicine and Surgery at Penn Medicine in Philadelphia, PA. In that role, he was in an academic-oriented practice for 10 years with a joint appointment in Urology and Reproductive Endocrinology (REI).

Dr. Masson is passionate about a comprehensive, integrated approach to male factor infertility in close collaboration with REI. He developed the male fertility program at Penn Medicine as part of the combined Penn Fertility Care experience, which was caring for approximately 500+ new male patients annually under his expertise. Dr. Masson has presented extensively on the clinical value of an integrated clinic with REI at the American Society of Reproductive Medicine (ASRM) and the American Urological Association (AUA) national meetings. He also established the fertility preservation program at Penn Medicine for oncology inpatients and outpatients as well as transgender patients interested in future fertility.

Dr. Thomas Masterson is an assistant professor of clinical urology in the Department of Urology at the University of Miami Miller School of Medicine and Bruce W Carter Miami VA Medical Center. He received his medical degree from the University of Miami Miller School of Medicine and completed his residency in Urology and fellowship in andrology at the University of Miami. Dr. Masterson is trained in microsurgery and infertility. He has experience operating with standard operating optical microscopes and 3D video microscopes. His clinical responsibility includes teaching medical student, residents, and andrology fellows. His research interests include treatment of male infertility, fertility preservation, testosterone replacement, male sexual dysfunction. He is co-investigator on an RO1 studying the safety and efficacy of combination shock wave therapy with platelet rich plasma to treat erectile dysfunction. Dr. Masterson is a reviewer for Fertility and Sterility, American Journal of Men’s Health, Lasers in Medicine, Frontiers in Endocrinology, Urology, and Andrology.

Dr. Mark Gonzalgo is professor and vice chair of urology, University of Miami Miller School of Medicine and Executive Director of Perioperative Surgical Services, University of Miami Health System. He also serves as director of the urologic oncology fellowship program. Dr. Gonzalgo is a urologic oncologist with expertise in robotic surgical approaches for the treatment of prostate, bladder, and kidney cancers. Dr. Gonzalgo is a recognized expert in DNA methylation and is particularly interested in developing new diagnostic and therapeutic approaches for cancer detection and treatment. He has carried out pioneering research on the molecular biology and early detection of prostate, bladder, and kidney cancer and has published extensively on the scientific and clinical aspects of these diseases. Dr. Gonzalgo has been recognized as a Top Doctor by US News & World Report and is an emeritus member of the scientific advisory board of the Bladder Cancer Advocacy Network (BCAN). He also currently serves as chair-elect of the American Urological Association (AUA) Office of Education.

Dr. Syan earned her medical degree at the University of Southern California, Keck School of Medicine (2008-2012) and completed her Urologic Surgery residency at New York University, Langone Medical Center from 2012-2017. Dr. Syan completed an ACGME-accredited fellowship at Stanford University in Female Pelvic Medicine and Reconstructive Surgery (2017-2019). As a fellow, Dr. Syan pursued specialized focuses of research interests, specifically in the fields of stress urinary incontinence, pelvic organ prolapse, and overactive bladder. She received grant funding through the 2017 SUFU Foundation Study of Chemodenervation as a Principal Investigator in a novel technique for delivering onabotulinumtoxinA (Botox®) to the bladder via a transvaginal route. As an Assistant Professor of Clinical Urology at the University of Miami Miller School of Medicine since 2019, Dr. Syan received grant funding support through the American Urologic Association as the Urology Care Foundation's 2021 Research Scholar to examine pelvic floor disorders among minority women and barriers to care they face and has current funding through the DSUI Pilot Grant Program Award FY24 to examine pelvic floor disorders in female bladder cancer survivors. She serves as an early career editor for the Journal of Urology, editorial board member for NeuroUrology and Urodynamics, and is a member of the SUFU Award Committee. Dr. Syan practices at UHealth as the Director of Female Urology at DSUI and specializes in female and male voiding dysfunction, pelvic organ prolapse, and neurourology.

Laura Horodyski, M.D., is a urologist with specialized training in trauma and reconstruction. She is passionate about helping patients with a range of urologic issues with the best medical and surgical care. Dr. Horodyski completed medical school at the University of Cincinnati, followed by a urology residency at the University of Miami Leonard M. Miller School of Medicine/Jackson Memorial Hospital. She also completed a clinical fellowship in trauma and reconstructive surgery at Temple University Hospital before returning to the University of Miami Health System’s Desai Sethi Urology Institute as faculty. Dr. Horodyski serves as the associate program director of the urology residency program.

Her clinical interests include treatment of complications from cancer treatment, urethral stricture, male stress urinary incontinence, erectile dysfunction, Peyronie’s disease, BPH, congenital and acquired urologic anomalies, and neurogenic bladder. She is an LGBTQ-affirming provider.

Dr. Sanoj Punnen, MD, is a Professor of Urology at the Desai Sethi Urology Institute. He completed his urology training at the University of Toronto and a fellowship in Urologic Oncology at the University of California, San Francisco.

Dr. Punnen has over ten years of experience managing complex tumors of the prostate, kidney, and bladder at the University of Miami Health System and the Sylvester Cancer Center. He provides comprehensive, innovative care personalized to each patient, prioritizing their treatment goals. Dr. Punnen specializes in minimally invasive robotic surgery to treat prostate, kidney, and bladder tumors and offers multidisciplinary cancer care for these conditions.

In addition to his clinical work, Dr. Punnen has a strong interest in cancer research and has enrolled over 500 men in NCI-sponsored clinical trials. Through clinical research, he brings the latest innovations and technology to his patients. He serves as Vice Chair of Clinical Research at the Desai Sethi Urology Institute, Assistant Director of Clinical Research at the Sylvester Comprehensive Cancer Center, and is the inaugural recipient of the Paps Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research.

Dr. Punnen is a compassionate and dedicated physician with expertise in multidisciplinary cancer care and minimally invasive surgery, helping patients overcome their fight against cancer.

Dr. Marcovich focuses on surgical and medical treatment of kidney stones. He is part of the DSUI Endourology Research group focusing on kidney stones and BPH. He also serves as Program Director of the DSUI-Jackson Urology Residency Program.

Dr. Ritch is a fellowship-trained Urologic Oncologist, and Associate Professor of Urology at the Desai Sethi Urology Institute, University of Miami, Miller School of Medicine where he is the Director of Urology for UHealth Tower, the flagship university hospital. His clinical interests include the treatment of prostate, bladder, kidney, and testicular cancer. His research interests are in prostate and bladder cancer. He oversees the institutional non-muscle invasive bladder cancer database at the University of Miami and has conducted a randomized controlled pilot trial investigating the role of nutrition intervention in patients undergoing radical cystectomy.

Dr. Ritch also has active research studies on prostate cancer in Afro-Caribbean men. He is a member of the American Urological Association (AUA) Guideline Panel for the Management of Non-muscle Invasive Bladder Cancer and co-developed the interactive guideline-based web app "BlaTUR" www.blatur.com to aid clinicians with the management of bladder cancer. He has an active role in the Society of Urologic Oncology (SUO) as the representative to the American College of Surgeons Commission on Cancer (CoC). He also serves on the Editorial Board for Urologic Oncology: Seminars and Original Investigations, the official journal of the SUO and is a member of the Board of Directors for International Volunteers in Urology (IVUmed). Dr. Ritch did his undergraduate studies at Duke University and then matriculated at the University of Chicago, where he obtained a joint degree in medicine (MD) and business (MBA) from the Pritzker School of Medicine and Booth School of Business. He then completed his residency in Urology at Columbia University Medical Center/NY Presbyterian Hospital followed by a two-year fellowship in Urologic Oncology at Vanderbilt University Medical Center.

Dr. Dipen J Parekh serves as the Professor and Chairman of the Urology Department at the University of Miami Miller School of Medicine. He is the holder of the Victor Politano Endowed Chair in Urology and serves as the Director of Robotic Surgery for the University of Miami Health System. In August 2017, Dr. Parekh was named Chief Clinical Officer of the University of Miami Health System. Dr. Parekh assumed responsibility of all UHealth outpatient and inpatient services, working closely with all department chairs and clinical faculty to enhance the clinical enterprise. In January 2020, Dr. Parekh was also named Chief Operating Officer for University of Miami UHealth System overseeing the health system’s operations while collaborating with many leaders on ambulatory strategy, inpatient clinical operations, optimizing the clinical care team model and advancing performance improvement efforts across the health system. In addition to his previous titles, in 2021 Dr. Parekh was named Executive Dean for Clinical Affairs at the Miller School of Medicine providing strategic counseling on enhancing the synergy between our academic and clinical missions.

In May of 2013 he was honored with the Gold Cystoscope Award, one of the most prestigious awards presented to one individual each year by the American Urological Association (AUA). He serves as Principal Investigator of the only National Cancer Institute RO1 Grant sponsored phase 3 multi-institutional clinical trial comparing open and robotic cystectomy for bladder cancer. He recently completed the first ever prospective clinical study on clamp renal ischemia during partial nephrectomy with transformative results.

Dr. Parekh is a board-certified, fellowship trained urologist specializing in urologic oncology using minimally invasive laparoscopic, robotic and traditional open approaches to treat prostate, bladder and kidney cancer and has performed over 5,000 robotic urologic procedures. Dr. Parekh has started several robotic surgery centers and programs of excellence both nationally and internationally. As part of his research interest, Dr. Parekh has been an active investigator in Urologic Oncology for the past 10 years predominantly in clinical trials and in translational research with a focus on prevention, detection, and treatment of genitourinary malignancies. He is the author of several scientific papers, abstracts and book chapters and has served as an Assistant editor for the Journal of Urology.

Dr. Parekh is a member of the American Urological Association, Endourology Society and Urology Society of India among other organizations.

Larry I. Lipshultz, M.D., is Professor of Urology and Chief of the Scott Department of Urology’s Division of Male Reproductive Medicine and Surgery. Dr. Lipshultz, who holds the Smith Chair in Reproductive Medicine, is a well-known authority on abnormalities of male reproduction, erectile dysfunction, and male hormone production. He received his medical training at the University of Pennsylvania and received fellowship training at The University of Texas at Houston as the first American Urological Association (AUA) research scholar. Recognized as a leading expert on men’s health, Dr. Lipshultz is a highly respected author and editor, as well as lecturer. Teacher as well as physician, researcher, writer, and editor, Dr. Lipshultz instituted a fellowship training program in male reproductive medicine and surgery that has trained more than 120 physicians who are now in practice both here and abroad.

Dr. Joseph P. Alukal is The Andrew Sabin Family Foundation Associate Professor in the Department of Urology; he is also Director of Men's Health at Columbia/New York-Presbyterian and Fellowship Director in Andrology/Male Reproductive Health. He serves as the Medical Director for Access-to-Care for Columbia Doctors.

Dr. Alukal serves in a number of roles at a national and international level for professional specialty and subspecialty organizations, including the American Urological Association (AUA), the American Society for Reproductive Medicine (ASRM), and the Society for the Study of Male Reproduction (SSMR), of which he is a past-President and current Board Member. As a member of the AUA Ambassadors, he have lectured internationally to the Urologic Professional Societies of countries including India, Italy, and Bangladesh.

He has authored or been a co-author on nearly 50 peer-reviewed publications and scientific book chapters and as well is the lead editor of the book "Design and Implementation of the Modern Men's Health Center." While as a fellow, he was funded by an AUA Foundation Award.

Dr. Alukal currently serves at Columbia in a number of roles, including his service on the Columbia Doctors PO Strategy Committee. As well, he is the Clinical Director for the NYP Reproductive Tissue Bank, in addition to serving on the NYP Tissue Bank Medical Advisory Committee.

He maintains a busy clinical practice in men's health, male infertility, male sexual dysfunction, and general urology and has been named to Castle Connolly's Top Doctors New York Metro Area every year since 2016. He is currently named to New York Magazine's Top Doctors 2024. He maintains extensive clinical collaborative relationships with numerous IVF centers, primary care, and cardiology practices in and around the New York City area. He has a Master's in Business Administration from Columbia Business School.

Brian Shuch, MD is a Professor, Department of Urology, at UCLA and Director of the Kidney Cancer Program and the SUO Fellowship in Urologic Oncology. He directs the UCLA VHL Program, a VHL Alliance Clinical Care Center and one of the largest on the west coast. Dr. Shuch graduated from NYU School of Medicine then completed his clinical training in urology at UCLA followed by fellowship training in urologic oncology at the NCI. Dr. Shuch serves as co-Chair of the NCI Renal Task Force and the SWOG Renal Committee and is on the Board of the KCA. He is an esteemed international lecturer on topics related to kidney cancer and hereditary cancer syndromes and his work has been published in leading journals such as Nature, Nature Genetics, Lancet, NEJM, Cancer Cell, and PNAS.

Dr. Jihad Kaouk is a board-certified urologist, internationally recognized as top expert in Urologic robotic surgery and innovation. As the Center for Robotic and Image-Guided Surgery director and Vice-Chair of Enterprise Surgical Operations at Cleveland Clinic, he has made significant contributions to the field. Additionally, Dr. Kaouk is a Professor of Surgery at the Cleveland Clinic Lerner College of Medicine and holds the Zegarac-Pollock Endowed Chair in Laparoscopic and Robotic Surgery.

Dr. Kaouk has performed more than 6000 robotic and minimally invasive Urologic surgeries. He has been a forerunner in surgical innovation, introducing several landmark procedures. Among his achievements are conducting the first robotic single port (SP) transumbilical surgery in 2008, pioneering the first entirely transvaginal nephrectomy in 2009, and developing the robotic perineal prostatectomy in 2014. He has also played a key role in integrating SP Robotic Surgery into urology, leading to breakthroughs such as the first SP extraperitoneal and transvesical robotic prostatectomies, along with groundbreaking SP extraperitoneal kidney transplantation and SP LAA, Low anterior access robotic partial nephrectomy procedures. Holding six U.S. patents for medical devices, he is also a co-founder and Chief Medical Officer of Method Surgical AI.

Since 2005, Dr. Kaouk has been actively involved in various committees at national and local levels. His roles have included membership in the American Urological Association’s (AUA) Urologic Diagnostic and Therapeutic Imaging Task Force and the Guidelines for the Management of Small Renal Masses Committee. He has served as chairman of the AUA New Technology and Imaging Committee and president of the Society of Urologic Robotic Surgery (SURS). Currently, he is the founder and Editor-in-Chief of the Urology Video Journal, president-elect of the Engineering and Urology Society (EUS), and Co-Director of the SP Marathon.

Dr. Kaouk's extensive experience includes lecturing at over 300 scientific meetings, chairing 34 urologic meetings, and performing live surgeries at 18 medical centers globally. With an h-index of 102 and more than 42,600 citations, he has authored over 620 peer-reviewed publications, 72 book chapters, and numerous abstracts and surgical movies. His achievements have been recognized with 62 awards, such as the Teacher of the Year Award, the Cleveland Clinic Innovator Award, the Endourology Best Fellowship Program Director Award, the International Innovations Award by the Vattikuti Foundation, and the AUA Distinguished Contribution Award. Expertscape ranks Dr. Jihad Kaouk as the world's top expert in Robotic Surgical Procedures and top Urologist in Cleveland published in Cleveland Magazine.

Dr. Karam is an Associate Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is certified by the American Board of Urology, and provides surgical care for men and women diagnosed with urologic malignancies, with a particular interest in renal, testicular and adrenal tumors. Dr. Karam received his bachelor's degree in Biology with Distinction and earned his medical degree with Distinction from the American University of Beirut. He completed a postdoctoral research fellowship in Tumor Biology in the Department of Urology at the University of Texas Southwestern Medical Center at Dallas, then completed Urology residency at the University of Texas Southwestern Medical Center at Dallas, followed by a two-year Urologic Oncology Fellowship in the Department of Urology at The University of Texas MD Anderson Cancer Center in Houston.

Dr. Karam’s primary clinical and research interest is renal cell carcinoma. He performs open surgery, laparoscopic surgery, as well as robotic surgery, individually tailored for the needs of patients with cancers of the kidney, testis and adrenal, with a special interest in surgery for locally advanced and locally recurrent disease. Dr. Karam has a research interest in integration of targeted therapy with surgery, sarcomatoid renal cell carcinoma, rare kidney cancer histologies including renal medullary carcinoma, mouse models of renal cell carcinoma and molecular markers. In collaboration with colleagues from urology and genitourinary medical oncology, he is also involved in clinical trials investigating targeted therapy prior to renal surgery. Dr. Karam has authored more than 160 articles in urologic oncology, including original research, book chapters, reviews, and invited editorials.

Dr. Karam is a member of the American Urological Association, the Society of Urologic Oncology, the American Society of Clinical Oncology, the American College of Surgeons, and the American Association for Cancer Research. He serves as a reviewer for over 20 journals, including Journal of Urology, European Urology, Urologic Oncology, BJU International, among others. Dr. Karam is also on the Editorial Board of BJU International, and serves as Associate Section Editor (Urologic Oncology) for Annals of Surgical Oncology, Section Editor (Urologic Oncology) for BMC Urology, and Associate Editor for Frontiers in Oncology (Genitourinary Oncology).

J. Quentin Clemens, MD, has published over 200 peer-reviewed manuscripts and book chapters. His research focuses on epidemiology and health services research related to benign urologic diseases, health policy, and quality of care assessment in urology. He has had continuous funding from the NIH since 2001. Dr. Clemens is currently the Principal Investigator for two NIH-funded research networks – the University of Michigan LURN Research Site and the University of Michigan MAPP Research Network. He has served as the Chair of the MAPP Network since 2013. His clinical interests include female urinary incontinence, complex fistulas and erosions, lower urinary tract reconstruction using bowel segments, bladder dysfunction due to neurologic disease, video urodynamic evaluation of complex lower urinary tract dysfunction, and interstitial cystitis/painful bladder syndrome.

Doreen Chung, M.D. specializes in male and female urinary incontinence, pelvic organ prolapse, female urology, and benign prostatic hyperplasia (BPH). She also has an interest in vaginal and minimally-invasive surgery for urinary incontinence and pelvic organ prolapse, artificial urinary sphincters for post-prostatectomy male incontinence, and laser procedures for the treatment of BPH (including vaporization and enucleation techniques).

Dr. Chung has published numerous articles and book chapters on these topics and is actively involved in clinical research. Her current investigations focus on clinical outcomes, biological graft use in the treatment of pelvic prolapse, and the effect of diabetes on voiding and incontinence.

Dr. Chung completed her medical degree and residency at the University of Toronto. Following her residency, she completed fellowships in voiding dysfunction, incontinence, and female urology at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center. Before joining Columbia, Dr. Chung was a Clinical Assistant Professor of Surgery at The University of Chicago Medicine. Dr. Chung is board certified in Urology as well as in the subspecialty of Female Pelvic Medicine and Reconstructive Surgery. She is a member of the American Urological Association, the American Urogynecologic Society, the International Continence Society and the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction.

Anne Pelletier Cameron, MD, FRCSC, URPS, the James Montie M.D. Legacy Professor of Urology at the University of Michigan and Vice Chair of Academic Affairs and Service Chief for the Department of Urology. She received her undergraduate degree at the University of New Brunswick. After completing her medical degree at the University of Ottawa and residency in urology at Dalhousie University, Dr. Cameron came to the University of Michigan for a fellowship in Female Pelvic Medicine and Reconstruction. Dr. Cameron remains at the university as an active clinician and participates in several research trials, including the NIDDK Funded LURN. Her clinical interests include complex incontinence, female urethral disease, and the care of neurogenic bladder.

Dr. Cameron is active with the Society of Women in Urology, serving as their past president and and active with the AUA serving on the Core Curriculum and Chair of the Overactive Bladder Guideline Committee. Dr. Cameron has also been very active with SUFU serving on the Executive Committee as their current Treasurer and awarded their Paul Zimskind research award in 2018.

Dr. Pinto is a Senior Investigator and faculty member in the Urologic Oncology Branch. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins Hospital. Dr. Pinto is a board certified urologic surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer. Dr. Pinto received tenure at NIH in 2023.

Rafael Sanchez-Salas is a surgeon and clinician scientist with main interest in minimally invasive treatments in Urological Oncology. He is an established leader in the emerging field of Focal Therapy for the treatment of Localized Prostate Cancer. Dr. Sanchez-Salas earned his Medical degree from the Universidad de los Andes in Mérida, Venezuela. He completed his basic Surgical and Urological training at Hospital Clinico Universitario at Universidad Central de Venezuela in 2005.

After fellowship training, he joined the Department of Urology at L’Institut Mutualiste Montsouris in Paris, France as Faculty from 2008 and until 2021. During his time in Paris, Dr. Sanchez-Salas worked extensively on robotic surgery and the development of partial gland ablation for Prostate Cancer treatment. He was responsible for the fellowship program organization at L’Institut Mutualiste Montsouris and he actively participated in the mentoring and training of a number of young urological surgeons.

Dr. Sanchez Salas has recently joined the Division of Urology at McGill University with the aim of further developing Localized Prostate Cancer and minimally invasive surgery research. Dr. Sanchez-Salas has coined a sound international career as a talented surgical proctor and cancer researcher.

Dr Sanchez-Salas serves on Boards of the Société International d’Urologie (SIU) and the Confederacion Americana de Urologia (CAU). He is among the founders members Focal Therapy Society.

Dr Sanchez-Salas is a member of the Editorial Board for “European Urology Focus”, “The Journal of Endourology Part B, Videourology” and “Actas Españolas de Urologia”. He is a Reviewer for major Urological and Oncological journals. He has authored over 200 indexed scientific papers.

Dr. Siemens is currently Professor and former Chair of the Department of Urology at Queen’s University. Dr. Siemens is cross-appointed to the Departments of Oncology as well as Biomedical and Molecular Sciences with a translational research focus on cancer immunotherapy, as well as an interest in health services research. He served as CUAJ editor until 2020 and has recently been named the Editor in Chief for The Journal of Urology.

Dan is the Director of Publications and Executive Editor for the American Urological Association and the founder of PIE (Publication Integrity & Ethics) Consulting, LLC. He has been in scholarly publishing for nearly three decades. Dan started in 1996 as a professional full-time editor for Physical Review B, published by the American Physical Society, and eventually advanced to the position of Editorial Director for the entire Physical Review portfolio. In 2020, he joined the Publications Division of the American Chemical Society (ACS) as Editorial Director and his most recent role with ACS was Senior Director, Research Integrity & Global Developments. Dan has degrees in Applied Mathematics (BS) from MIT and Material Science and Engineering (PhD) from the University of Pennsylvania. He has been involved in all aspects of publishing including peer review, publication ethics, production, distribution, and personnel and financial management of journals.

Dr. Mantu Gupta is Professor of Urology, Icahn School of Medicine at Mount Sinai, Chair of Urology at Mount Sinai West and Mount Sinai Morningside Hospitals, and Director of the Mount Sinai Kidney Stone Center, and Director of Endourology and Stone Disease for the Mount Sinai Health System.

Dr. Gupta is recognized as a world leader in the research and treatment of urinary stone disease, ureteropelvic junction obstruction, urinary tract obstruction, and upper tract urothelial malignancies, having pioneered many of the techniques in current use, including Noninvasive Office-based Escalating Voltage Shock Wave Lithotripsy, Totally Tubeless Ultrasound-guided Supine-position Outpatient MiniPCNL, and X-ray-free Stent-free Ureteroscopy. He is recognized as one of the leading endoscopic, percutaneous, and minimally invasive surgeons in the world, having performed over 20,000 major endourological procedures.

Dr. Gupta is unique in that he employs a nurturing, compassionate, and holistic approach to the management of stone disease, utilizing alternative medical, nutritional and preventive strategies. Prior to joining Mount Sinai, Dr. Gupta served as Associate Professor, Director of Endourology and Director of the Kidney Stone Center at Columbia University Medical Center for18 years.

The recipient of numerous honors and awards, Dr. Gupta was given a Presidential Gold Medal by President Ronald Reagan for his academic achievements and has served as a visiting professor both within the United States and throughout the world. He is a frequent lecturer and moderator at national and international meetings and has published extensively in major peer-reviewed journals and authored numerous book chapters. Additionally, Dr. Gupta teaches various surgical skills courses throughout the world and is currently Editor-in-Chief of Videourology and has served as editor and guest editor for numerous publications including the Journal of Endourology, the Journal of Urology, the Indian Journal of Urology, and Urology.

Dr. Gupta was a member of the prestigious Honors Program in Medical Education at Northwestern University where he earned a combined BS-MD degree with distinction and was elected to the Alpha Omega Alpha Honor Society. He subsequently did his Urology residency at the top ranked University of California at San Francisco and completed a fellowship in Endourology at Long Island Jewish Medical Center under the tutelage of the founding father of Endourology.

Dr. Dean S. Elterman completed his medical degree followed by residency in urologic surgery at the University of Toronto. He became a fellow of the Royal College of Physicians and Surgeons of Canada in 2011. Dr. Elterman completed a two-year fellowship in Voiding Dysfunction, Neuro-Urology, Female Urology and Pelvic Reconstruction at Memorial Sloan-Kettering Cancer Center and New York Presbyterian Hospital/Weill Cornell Medical College in New York City.

Dr. Elterman has worked in the areas of men’s health and survivorship at the Iris Cantor Men’s Health Center at New York Presbyterian Hospital/Weill Cornell Medical College and at the University of Toronto. He is the Medical Director of the Prostate Cancer Rehabilitation Clinic at Princess Margaret Hospital Cancer Centre.

He completed his Masters degree in Clinical Epidemiology and Health Services Research at Weill Cornell Graduate School of Medical Sciences.

Dr. Elterman is a member of several professional societies including the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, the Society of Genitourinary Reconstructive Surgeons, the International Neuromodulation Society, and the International Society of Men’s Health.

Dr. Bochner is a Member at Memorial Sloan Kettering Cancer Center on the Urology Service and a Professor in the Department of Urology at the Weill Medical College of Cornell University. Currently, Dr. Bochner is the inaugural holder of the Sir Murray Brennan Endowed Chair in Surgery at MSKCC. He served as a Vice-Chairman of the Department of Surgery and is the immediate past co-Director of the Pelvic and Reconstructive Surgery group at Memorial Sloan-Kettering Cancer Center.

David D. Thiel, M.D., is a physician in the Department of Urology at Mayo Clinic Hospital in Jacksonville, Florida with a joint appointment in the Division of Epidemiology, Department of Health Sciences Research. He has served as chair of the Department of Urology and the director of Robotic Surgery. Dr. Thiel's clinical interests include laparoscopic and robotic surgery for malignant and benign urologic conditions, specifically nephron sparing surgery for kidney cancer and robotic prostatectomy.

Dr. Thiel received his medical degree from the University of Cincinnati College of Medicine. He then completed an internship in general surgery and residency at Mayo Clinic Hospital in Jacksonville, as well a fellowship in endourology, robotics and laparoscopy at the University of Iowa Hospitals and Clinics.

Dr. Thiel received the Mayo Clinic Distinguished Educator award in 2017, and the Outstanding Faculty Award in 2007, both from Mayo Clinic College of Medicine and Science. He has been featured in more than 100 peer-reviewed publications. He has received numerous other awards and honors, including being recognized — five times — as one of the top doctors in Jacksonville by Jacksonville Magazine, and being named among the 40 Most Influential People in Medicine by 904 Magazine in Jacksonville.

Dr. Sijo Parekattil is Director of Avant Concierge Urology, Winter Garden, FL and an Associate Professor of Urology at the University of Central Florida (UCF). He was an Electrical Engineer (University of Michigan) prior to his medical training and thus has interests in surgical techniques incorporating technology, robotics and microsurgery. He completed his urology residency training at Albany Medical Center and then went onto complete dual fellowship training from the Cleveland Clinic Foundation, Cleveland in Laparoscopy/Robotic Surgery and Microsurgery/Male Infertility. He is one of the only urologists in the country with this type of dual fellowship training background.

Dr. Parekattil has received numerous awards including two Annual Innovator Awards from the Cleveland Clinic Foundation and the Golden Garland Award in Medicine in 2012. He has published several articles in the field of robotic microsurgery and microsurgery. He is an editor on a few textbooks on Male Infertility and a surgical textbook on Robotic Microsurgery. He has performed some pioneering work in the arena of microsurgery and has performed well over 3000 such procedures. He has developed a multi-disciplinary program dedicated to the treatment of male infertility and groin/testicular pain. He is also a Visiting Professor at the University of Zambia, Lusaka, Africa.

He is one of the founding Board members of the Robotic Assisted Microsurgical & Endoscopic Society (RAMSES), a group focused on the evidence-based development of tools and platforms for robotic-assisted microsurgery, and the International Microsurgical Simulation Society (IMSS), a group focused on developing more standardized and effective microsurgical training techniques. He is on the foundation board for the Florida Polytechnic University, Lakeland, FL, and an Executive Board Member of the Florida Urological Society.

Dr. Merchan is a tenured Professor of Medicine in the division of Medical Oncology. He is the Co-leader of the Translational and Clinical Oncology Research Program, the Director of the Phase 1 Clinical Trials Program, and the Associate Director of the NIH funded Calabresi Clinical Oncology Research Career Development Award. As a physician scientist, his contributions to science include redefining the role of the plasminogen activator system in cancer progression, the development of novel preclinical and clinical strategies to overcome resistance in RCC and angiogenesis dependent cancers, and the preclinical and clinical development of tumor and stromal targeted oncolytic viruses and virus-drug combinations. He leads the only academic phase I program in South Florida, bringing novel treatment strategies to many patients with advanced cancer. Dr. Merchan has an established track record in translational cancer research, bringing lab discoveries to the clinic, and has been involved in the development of novel, effective treatment strategies in genitourinary cancers, which resulted in practice changing publications and introduced new treatment options for cancer patients.

After obtaining his MD degree in Rio de Janeiro, Brazil in 2005, Dr. Bruno Nahar completed a 2-year residency in General Surgery followed by a 3-year residency in Urology, leading to his Board Certification in Urology in Brazil. He worked as faculty at a large hospital in Rio de Janeiro for 4 years before pursuing further training. Dr. Nahar completed a 2-year Clinical Fellowship in Urologic Oncology and Robotic Surgery at the University of Miami Miller School of Medicine/ Sylvester Comprehensive Cancer Center.

Dr. Nahar's exceptional dedication and contributions to the field of Urologic Oncology have recently been recognized with the prestigious Eric and Elizabeth Feder endowed chair for Urologic Oncology research. This honor highlights his remarkable expertise and outstanding achievements in urologic cancer care.

Currently, Dr. Nahar serves as an Assistant Professor of Urologic Oncology at the University of Miami, where he continues to make significant advancements in the field. His particular focus lies in the study and treatment of malignant conditions affecting the prostate, kidney, and bladder. Dr. Nahar's comprehensive knowledge and innovative approach have positioned him as a pioneer in the field of Focal Therapy for the treatment of prostate cancer.

Throughout his career, Dr. Nahar has made significant contributions to Urologic Oncology research. He has authored numerous publications and books, solidifying his position as a respected authority in the field. Due to his expertise and reputation, Dr. Nahar serves as a reviewer for all major academic journals, providing valuable insights and guidance to fellow researchers and medical professionals.

With his extensive training, passion for patient care, and groundbreaking research, Dr. Bruno Nahar continues to shape the landscape of Urologic Oncology, bringing hope and improved outcomes to countless individuals affected by urologic cancers.

Dr. Thompson received his BS from West Point and MD from Tulane. After a Urology Residency in San Antonio and a Urologic Oncology fellowship at Memorial Sloan Kettering Cancer Center, he was Chair of Surgery at Brooke Army Medical Center until retiring from the Army in 2000. He was the founding Chair of the Department of Urology and Director of the Cancer Therapy and Research Center at UT Health Science Center at San Antonio. Upon retiring from UT in 2017, he became President of CHRISTUS Santa Rosa Medical Center Hospital and thereafter, The CHRISTUS Children’s Foundation.

Dr Thompson served as the Chair of the Early Detection Research Network of the NCI, Chair of the GU Committee of SWOG, chaired the Urology Residency Review Committee, was President of the Society of Urologic Oncology, and President of the American Board of Urology and most recently, served five years on the Board of Scientific Advisors of the NCI. He served as Principal Investigator of many practice-changing, phase 3 clinical trials of the National Cancer Institute.

Among his awards include the Legion of Merit from the Department of Defense, Charles Huggins Medal from the Society of Urologic Oncology, Hugh Hampton Young Award from the AUA, Distinguished Alumnus Award from Memorial Sloan Kettering Cancer Center, Honorary Membership of the AUA, the Canadian Urological Association, and the Mexican Urological Association, and AUA’s Ramon Guiteras Award.

Dr. Ojas Shah is the George F. Cahill Professor of Urology at Columbia University College of Physicians and Surgeons. He also serves as the Director of the Division of Endourology and Stone Disease at Columbia University Medical Center. His clinical and research interests include surgical and metabolic treatments of kidney stone disease, minimally invasive urologic surgery, upper urinary tract urothelial carcinoma (transitional cell carcinoma), ureteral strictures, ureteropelvic junction (UPJ) obstruction, ureteral/renal reconstructive surgery, and BPH (benign prostate hyperplasia). He serves as the principal investigator in many clinical research trials regarding the surgical or medical management of stone disease.

He is a graduate of the Honors Program in Medical Education at Northwestern University School of Medicine. He completed his general surgical and urologic training at New York University Medical Center. He spent an additional year at Wake Forest University Health Sciences Center as a fellow in endourology, laparoscopy and metabolic stone disease.

Dr. Shah is a nationally and internationally recognized expert in the medical and surgical management of patients with urinary stone disease. He recently served as a member of the American Urological Association's Surgical Management of Stones Guidelines Committee. He was also recently appointed to the American Board of Urology's Examination Committee. He is an active member of the Endourological Society, EDGE (Endourology Disease Group for Excellence) Research Consortium, and ROCK (Research on Calculous Kinetics) Society.

Dr Smith's career has been focused on innovative surgical treatment for urologic cancer. He has transitioned from his surgical practice at Vanderbilt and now is Director of Global Surgery for the Department. He oversees and participates in humanitarian surgical efforts throughout the world and coordinates the participation of residents, fellows, and other faculty at Vanderbilt.

Dr Smith's career has been focused on innovative surgical treatment for urologic cancer. He has transitioned from his surgical practice at Vanderbilt and now is Director of Global Surgery for the Department. He oversees and participates in humanitarian surgical efforts throughout the world and coordinates the participation of residents, fellows, and other faculty at Vanderbilt.

Dr Smith's career has been focused on innovative surgical treatment for urologic cancer. He has transitioned from his surgical practice at Vanderbilt and now is Director of Global Surgery for the Department. He oversees and participates in humanitarian surgical efforts throughout the world and coordinates the participation of residents, fellows, and other faculty at Vanderbilt.

Dr. Marijo Bilusic, MD, PhD, is a board-certified medical oncologist who treats genitourinary tumors (adrenal, kidney, prostate, bladder, and testis). His current research interests focus on tumor immunology and the development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, immune modulators or immune checkpoint inhibitors, not only as monotherapies but in combination with other immune mediating modalities and other conventional or experimental therapies as part of an immuno-oncology programmatic effort.

Dr. Bilusic received his M.D. degree from the University of Zagreb School of Medicine in Croatia and completed his Ph.D. training at the University of Split School of Medicine in Croatia. In addition, he completed a postdoctoral research fellowship in physiological genomics at the Medical College of Wisconsin's Human and Molecular Genetics Center in Milwaukee, WI. He completed a clinical fellowship in medical oncology and hematology at the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI), in Bethesda, MD.

Dr. Bilusic served as an assistant professor (Genitourinary medical oncology) at the Fox Chase Cancer Center/Temple Health from 2012 – 2016 and then joined the NCI Genitourinary Malignancy Branch in 2016 as an Associate Research Physician (equivalent to Associate Professor). During his time at the NCI, he also served as Associate Program Director, NIH Hematology Oncology Fellowship Program from July 2016 – July 2018, and then as Program Director from July 2018 – July 2021. In 2017 Dr. Bilusic received the National Institutes of Health (NIH) Director's Award as a member of NIH Hematology Oncology Fellowship Team for extraordinary resourcefulness and initiative. His passion for teaching and mentoring has earned multiple awards at NIH and NCI.

In July 2021, Dr. Bilusic joined Sylvester Comprehensive Cancer Center / University of Miami Health System as GU Medical Oncology Team Lead and Professor of Clinical Medicine. He is board-certified in medical oncology, hematology, and internal medicine.

Dr. Hemendra N. Shah is Professor of Urology at Desai Sethi Urology Institute and Miller School of Medicine at University of Miami. He is also fellowship director for Endourology Society accredited fellowship at DSUI. He received his urology training from Grant Medical College and Sir J. J. Hospital in Mumbai, India was awarded “Dr. Dipak L. Kothari Gold Medal” by Mumbai University and “The H. L. Bhatt Gold Medal” by National Board of Examinations for securing top rank in country in urology exit examinations. He is also awarded membership of Royal College of Surgeons of Edinburgh and AUA- IAUA Chakraborty fellowship in 2012. He has published over 100 manuscripts in peer-reviewed journals and have presented numerous papers in various national and international conferences. He is the member of several professional societies and reviewer of various international journals. He is also an editorial board member of World Journal of Urology and Scientific Reports.

Dr. Shah’s primary research interests lie in endourology, lithotripsy, and laser prostatectomy. He specializes in Holmium Laser Enucleation of the Prostate (HoLEP) and the endourological management of nephrolithiasis, urothelial tumors, and complex ureteric strictures. As one of the early adopters of HoLEP, he has been at the forefront of this technique for over 20 years. Dr. Shah has mentored and trained more than 100 urologists in advanced endourology and laser techniques, with a particular focus on percutaneous nephrolithotomy (PCNL), flexible ureteroscopy, and HoLEP.

Dr. Brian Eisner is the Co-Director of the Kidney Stone Program at the MGH. He specializes in kidney stone surgery, kidney stone prevention, endourology and related research.

He serves as the Medical Director of the Massachusetts General Hospital Department of Urology and the Chief of the Division of Urology at Newton Wellesley Hospital.

Dr. Eisner was born in Miami, FL and attended Harvard College and the University of Michigan Medical School. He completed urology residency training at Massachusetts General Hospital and a fellowship in endourology and urinary stone disease at the University of California, San Francisco. His clinical practice focuses on kidney stone prevention, minimally invasive and surgical treatments for kidney stones, and endourology. He is actively involved in research involving kidney stone prevention, risk factors for kidney stone disease, and surgical treatment of kidney stones.

My name is Padraic O’Malley, MSc, MD, FRCSC, and I am a clinical assistant professor in the University of Florida Department of Urology and chief of urologic oncology. Following medical school at Saba University School of Medicine, I completed my urology residency at the University of Toronto in Toronto, Canada, where I was awarded the Undergraduate Teaching Award. I completed my urologic oncology fellowship at Weill-Cornell Medical College in New York, New York, where I was awarded the Ferdinand C. Valentine Fellowship Award. I joined UF Health in 2018 and have since been awarded a UF College of Medicine Exemplary Teacher award as well as the Department of Urology Rising Star Award.

Currently, I am a board member of the Florida Urological Society and Southeastern section of the American Urological Association. I am also a member of the American Urological Association, the Canadian Urological Association, the Endourological Society and the Society of Urologic Oncology, in addition to being an international member of the European Association of Urology. Along with seeing patients and teaching, I have contributed as an author to a number of urology-based publications, chapters and abstracts.

My clinical interests revolve around urologic oncology, multidisciplinary care and robotic surgical techniques. I perform complex robotic surgery with a special interest in bladder and kidney cancer. This includes treating IVC thrombus, performing robotic and open tumor thrombectomies, and robotic and open retroperitoneal lymph node dissection. I serve as a sub-investigator on a number of clinical trials for bladder, kidney and prostate cancer. My research interests examine the tumor microenvironment in bladder and kidney cancer, the use of novel nanoparticle and artificial intelligence-powered analysis of exosome-based, multi-fluid multi-omics in bladder cancer, and the use of surgery in advanced kidney cancer.

Timothy D. Lyon, M.D., is an Associate Professor of Urology and the Urology Residency Program Director at Mayo Clinic in Jacksonville, Florida. He also serves as the Clinical Director of the Kern Scholars Program in the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Dr. Lyon received his medical degree from the University of Kansas and was a resident in Urology at the University of Pittsburgh Medical Center. He subsequently completed a 2-year fellowship in Urologic Oncology at Mayo Clinic in Rochester, Minnesota, where he developed subspecialty expertise in the multidisciplinary management of complex urologic cancers.

Dr. Victoria Bird started her career as an Assistant Professor of Urology at the University of Miami and nearby Veterans Administration Hospital -with an emphasis on Prostate cancer care.

Later, she joined the University of Florida's Department of Urology, College of Medicine, as an Assistant Professor and as an Affiliate faculty at the College of Engineering at the University of Florida.

Dr. Bird believes in personalized patient centered medicine and has received multiple patient care awards. Her research has been presented nationally and internationally.

She is published in a number of scientific journals with emphasis in prostate cancer, testosterone physiology, kidney stones, and infections of the urinary tract.

Raymond Pak, M.D., is a physician in the Department of Urology at Mayo Clinic in Jacksonville, Florida. He has an expertise in minimally invasive laparoscopic, robotic and endoscopic surgery. He specializes in urologic cancers (prostate, kidney, ureter and bladder), obstructions (ureter), voiding dysfunction from BPH and kidney stone disease.

Dr. Pak received his Bachelor of Science and Doctorate of Pharmacy degrees from Rutgers University, followed by a medical degree from Rutgers New Jersey Medical School. He completed his residency in general surgery and urologic surgery at the Mayo Clinic in Jacksonville, Florida. He then pursued fellowship training in minimally invasive oncology and stone surgery at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.

Prior to joining the faculty of Mayo Clinic Florida, he served as the medical director of robotic surgery for Jenkins Clinic and Piedmont Hospital in Atlanta, Georgia where he also obtained an MBA from the Scheller College of Business at the Georgia Institute of Technology. He currently serves as an adjunct professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech College of Engineering and Emory School of Medicine. His research interests are focused on the application of technology to deliver better surgical and medical care to patients.

Dr. Pak has authored numerous peer-reviewed articles, book chapters and abstracts. In addition, he has travelled internationally to present his work. Dr. Pak is board certified by the American Board of Urology.

Dr. Shrikanth Atluri is a highly experienced uro-oncologist and robotic surgeon specializing in the treatment of all types of urologic cancers, particularly utilizing advanced robotic surgical techniques.

Dr. Shrikant Atluri graduated with his initial undergraduate (MBBS) qualification from the premier B J G Medical College, Pune, MUHS, receiving several distinctions. Continuing his academic journey, he pursued and successfully completed his Masters in General Surgery (M.S.) at the prestigious Seth G.S. Medical College and K.E.M Hospital, Mumbai, where he excelled and ranked second in the department. Dr. Atluri later achieved his M.Ch. in Urology from the renowned Bombay Hospital Institute of Medical Sciences, Mumbai, following a rigorous 3-year training program in Urology.

During his residency, Dr. Atluri discovered a passion for urologic oncology and dedicated himself to pursuing it as his career. With five years of intensive and specialized training in urologic malignancies from leading institutions in India and the USA, he has gained unparalleled expertise.

I am a board-certified urologic surgeon who specializes in surgery for patients with genitourinary cancers. My expertise is in the clinical care and surgical treatment of patients with testicular cancer. I work closely with colleagues from medical oncology, pathology, radiology, and radiation therapy to provide the most effective treatment for our patients, as well as to establish the optimal multidisciplinary approach for all patients with testicular cancer.

I have developed surgical techniques to preserve patients’ fertility through the use of “nerve sparing” retroperitoneal lymph node dissection (RPLND). This approach is appropriate for most patients who have low-stage disease and for many patients with more-advanced cancers who have completed treatment with chemotherapy. For the past decade I have performed approximately 100 RPLNDs per year. Because of my particular expertise in retroperitoneal surgery, I also work with specialists in other disciplines to surgically manage different types of tumors in the retroperitoneum.

I have written numerous articles and book chapters on testicular cancer care and frequently speak on the topic at national and international forums. As an established leader in testicular cancer I have edited special editions on this disease in Urologic Clinics of North America, the World Journal of Urology, the British Journal of Urology, Urologic Oncology, and Seminars in Urologic Oncology. Furthermore, I have written or co-authored the chapter on the surgical management of testicular cancer for the major textbooks in urology (Campbell’s Urology, 8th, 9th, and 10th editions) and oncology (DeVita’s Principles and Practice of Oncology, 5th, 6th, 7th, 8th, and 9th editions).